Literature DB >> 26639975

Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.

Anna Malishkevich1, Gad A Marshall2,3, Aaron P Schultz3, Reisa A Sperling2,3, Judith Aharon-Peretz4, Illana Gozes1.   

Abstract

Biomarkers for Alzheimer's disease (AD) are vital for disease detection in the clinical setting. Discovered in our laboratory, activity-dependent neuroprotective protein (ADNP) is essential for brain formation and linked to cognitive functions. Here, we revealed that blood borne expression of ADNP and its paralog ADNP2 is correlated with premorbid intelligence, AD pathology, and clinical stage. Age adjustment showed significant associations between: 1) higher premorbid intelligence and greater serum ADNP, and 2) greater cortical amyloid and lower ADNP and ADNP2 mRNAs. Significant increases in ADNP mRNA levels were observed in patients ranging from mild cognitive impairment (MCI) to AD dementia. ADNP2 transcripts showed high correlation with ADNP transcripts, especially in AD dementia lymphocytes. ADNP plasma/serum and lymphocyte mRNA levels discriminated well between cognitively normal elderly, MCI, and AD dementia participants. Measuring ADNP blood-borne levels could bring us a step closer to effectively screening and tracking AD.

Entities:  

Keywords:  Activity-dependent neuroprotective protein (ADNP); Alzheimer’s disease; amyloid-beta; blood-borne biomarkers; cognitively normal; mild cognitive impairment; premorbid intelligence

Mesh:

Substances:

Year:  2016        PMID: 26639975      PMCID: PMC4712084          DOI: 10.3233/JAD-150799

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  51 in total

1.  Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.

Authors:  Gad A Marshall; Natacha Lorius; Joseph J Locascio; Bradley T Hyman; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

3.  Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia.

Authors:  Efrat Dresner; Galila Agam; Illana Gozes
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-03       Impact factor: 4.600

4.  Activity-dependent neuroprotective protein modulates its own gene expression.

Authors:  Moutasem S Aboonq; Sylvia A Vasiliou; Kate Haddley; John P Quinn; Vivien J Bubb
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

5.  Activity-dependent neuroprotector homeobox protein: A candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease.

Authors:  Ming-Hui Yang; Yuan-Han Yang; Chi-Yu Lu; Shiang-Bin Jong; Li-Jhen Chen; Yu-Fen Lin; Shyh-Jong Wu; Pei-Yu Chu; Tze-Wen Chung; Yu-Chang Tyan
Journal:  J Proteomics       Date:  2012-04-21       Impact factor: 4.044

6.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Authors:  Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

7.  Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.

Authors:  Sharon Furman; Ruth A Steingart; Shmuel Mandel; Janet M Hauser; Douglas E Brenneman; Illana Gozes
Journal:  Neuron Glia Biol       Date:  2004-08

8.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

9.  Cognition, reserve, and amyloid deposition in normal aging.

Authors:  Dorene M Rentz; Joseph J Locascio; John A Becker; Erin K Moran; Elisha Eng; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

10.  Amyloid-β associated cortical thinning in clinically normal elderly.

Authors:  J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

View more
  26 in total

Review 1.  Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.

Authors:  Yanina Ivashko Pachima; Liu-yao Zhou; Peng Lei; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02       Impact factor: 3.444

2.  Tau Diagnostics and Clinical Studies.

Authors:  Illana Gozes; Günter Höglinger; James P Quinn; Nigel M Hooper; Kina Höglund
Journal:  J Mol Neurosci       Date:  2017-10       Impact factor: 3.444

3.  Postmortem Brain, Cerebrospinal Fluid, and Blood Neurotrophic Factor Levels in Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Authors:  Yang Du; Huan-Tong Wu; Xiao-Yan Qin; Chang Cao; Yi Liu; Zong-Ze Cao; Yong Cheng
Journal:  J Mol Neurosci       Date:  2018-06-28       Impact factor: 3.444

4.  The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-11       Impact factor: 3.444

5.  ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.

Authors:  Y Ivashko-Pachima; C Laura Sayas; A Malishkevich; I Gozes
Journal:  Mol Psychiatry       Date:  2017-01-24       Impact factor: 15.992

6.  ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging.

Authors:  Oxana Kapitansky; Illana Gozes
Journal:  Geroscience       Date:  2019-07-01       Impact factor: 7.713

7.  Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer's disease: a meta-analysis study (N=7277).

Authors:  X-Y Qin; C Cao; N X Cawley; T-T Liu; J Yuan; Y P Loh; Y Cheng
Journal:  Mol Psychiatry       Date:  2016-04-26       Impact factor: 15.992

Review 8.  Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2017-09-04       Impact factor: 6.543

9.  Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome.

Authors:  Gal Hacohen-Kleiman; Shlomo Sragovich; Gidon Karmon; Andy Y L Gao; Iris Grigg; Metsada Pasmanik-Chor; Albert Le; Vlasta Korenková; R Anne McKinney; Illana Gozes
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

10.  Sex-and Region-Dependent Expression of the Autism-Linked ADNP Correlates with Social- and Speech-Related Genes in the Canary Brain.

Authors:  Gal Hacohen-Kleiman; Stan Moaraf; Oxana Kapitansky; Illana Gozes
Journal:  J Mol Neurosci       Date:  2020-09-14       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.